Cirrhosis/Liver Failure News

A pair of preoperative and postoperative models estimated the probabilities for post-hepatectomy liver failure in patients with cirrhosis, according to a recently published study.

Liver disease in children and adolescents takes on as many forms as in adults, including viral hepatitis, autoimmune diseases, fatty liver disease, and even the pediatric-specific biliary atresia that occurs in infants.

Mallinckrodt announced the first patient has been enrolled in a phase 2a trial comparing MNK-6106, an L-ornithine phenylacetate, with Xifaxan for the treatment of liver cirrhosis and hepatic encephalopathy, according to a press release.

Intake of a multistrain probiotic improved cognitive function, risk for falls and inflammatory response in patients with cirrhosis and a history of cognitive impairment and previous falls, according to a study published in Hepatology Communications.

Results from a systematic review and meta-analysis revealed the global prevalence of fatty liver disease in patients with type 2 diabetes, ranging from approximately 55% for nonalcoholic fatty liver disease to 37% for nonalcoholic steatohepatitis, affected specifically by region and age.

Liver stiffness measured by 2D ShearWave Elastography demonstrated significant predictive value in the progression of chronic liver disease including associated complications and mortality, according to a press release from SuperSonic Imagine and a poster presented at the International Liver Congress 2019.

The American College of Gastroenterology released a new clinical guideline for the screening, diagnosis and treatment of hereditary hemochromatosis, a genetic disease that alters the body’s ability to regulate iron absorption and one of the most common genetic disorders among people of northern European descent.

Stephen A. Harrison, MD, FACP, FAASLD, visiting professor of hepatology at University of Oxford and medical director at Pinnacle Clinical Research, discussed how the growing epidemic of liver disease impacts the financial solvency of the U.S. health care system in a white paper released by Echosens.

The American Association for the Study of Liver Diseases Foundation has granted $3.42 million in research and career development awards to 29 researchers and clinicians to conduct liver disease research and undergo advanced hepatology training.

Dicerna Pharmaceuticals submitted a clinical trial authorization application to the Swedish Medical Products Agency to conduct a phase 1/2 study of DCR-A1AT for the treatment of alpha-1 antitrypsin deficiency-related liver disease, according to a press release.